<?xml version="1.0" encoding="UTF-8"?>
<ref id="B20">
 <label>20</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bathgate</surname>
    <given-names>RAD</given-names>
   </name>
   <name>
    <surname>Kocan</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Scott</surname>
    <given-names>DJ</given-names>
   </name>
   <name>
    <surname>Hossain</surname>
    <given-names>MA</given-names>
   </name>
   <name>
    <surname>Good</surname>
    <given-names>SV</given-names>
   </name>
   <name>
    <surname>Yegorov</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting</article-title>. 
  <source>Pharmacol Ther</source> (
  <year>2018</year>) 
  <volume>187</volume>:
  <page-range>114–32</page-range>.  
  <pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.02.008</pub-id>
 </mixed-citation>
</ref>
